TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

M Schlumberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.